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ABSTRACT:  Rare variants have been shown to be significant contributors to complex disease risk.  By definition, 
these variants have very low minor allele frequencies and traditional single-marker methods for statistical analysis 
are underpowered for typical sequencing study sample sizes.  Multi-marker burden-type approaches attempt to 
identify aggregation of rare variants across case-control status by analyzing relatively small partitions of the 
genome, such as genes.  However, it is generally the case that the aggregative measure would be a mixture of causal 
and neutral variants, and these omnibus tests do not directly provide any indication of which rare variants may be 
driving a given association.  Recently, Bayesian variable selection approaches have been proposed to identify rare 
variant associations from a large set of rare variants under consideration.  While these approaches have been shown 
to be powerful at detecting associations at the rare variant level, there are often computational limitations on the total 
quantity of rare variants under consideration and compromises are necessary for large-scale application.  Here, we 
propose a computationally efficient alternative formulation of this method using a probit regression approach 
specifically capable of simultaneously analyzing hundreds to thousands of rare variants.  We evaluate our approach 
to detect causal variation on simulated data and examine sensitivity and specificity in instances of high rare variant 
dimensionality as well as apply it to pathway-level rare variant analysis results from a prostate cancer risk case-
control sequencing study.  Finally, we discuss potential extensions and future directions of this work. 
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INTRODUCTION 
With advancements in next-generation sequencing technologies, there has been a reinvigorated interest in 
the roles that rare variants (RVs) play in the genetic etiology of complex diseases [Cirulli and Goldstein 2010].  Due 
to low minor allele frequencies (MAFs), traditional single-variant risk association analysis methods on RVs suffer 
from low statistical power for even relatively large sample sizes, and specialized strategies are necessary to identify 
RV associations.  This has led to the development of multi-marker aggregation strategies that are predicated on the 
notion that causal RVs may cluster in biologically relevant functional domains, such as genes [Bansal, et al. 2010].  
There are a growing number of multi-marker omnibus methods available for RV association analysis that evaluate a 
priori defined target regions of interest (ROI) to localize clustering of causal RVs.  These include various burden-
based collapsing methods [Dering, et al. 2011], as well as variance component tests such as the C-alpha test [Neale, 
et al. 2011] and sequence kernel association test (SKAT) [Lee, et al. 2012; Wu, et al. 2011]. 
A notable caveat for these omnibus tests is that they do not provide any inference at the marker level as to 
which RVs may be driving a given multi-marker association.  An alternative strategy is to simultaneously assess all 
of the RVs under consideration and apply some form of variable selection.  One approach to identifying these RVs 
is to apply Bayesian variable selection procedures (for review, see [O'Hara and Sillanpaa 2009]).  Use of these 
methods in marker association studies have the potential to be more powerful than other model selection procedures 
[Quintana and Conti 2013; Wilson, et al. 2010], and additionally provide relevant posterior quantities of interest for 
variable inclusion.  Recently, Bayesian model uncertainty (BMU) strategies have been proposed for RV association 
analysis in case-control studies, referred to as the Bayesian risk index (BRI) [Quintana, et al. 2011].  The BRI 
method utilizes an aggregation and collapsing risk index parameterization of the selected RVs in a logistic 
regression framework, which we hereafter refer to as L-BRI.  The authors’ simulation results not only indicate 
increased power over traditional omnibus approaches for global association, but powerful detection of individual 
RVs driving an association signal through the derivation of marginal Bayes Factors (BFs). 
A drawback of selecting the logit link function for the generalized linear model is that no closed-form 
solutions exist for the full conditional densities of the model parameters.  Moreover, the Metropolis-Hastings (MH) 
algorithm for sampling from the model space in L-BRI applies a single-component proposal procedure to the 
variable inclusion vector.  This can result in a computationally intensive algorithm requiring many hours to run to 
fully explore the model space for higher RV counts, reserving practical applications to smaller regions of the 
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genome.  Recent findings from large-scale sequencing studies indicate that, from a population-based perspective, 
RV sites can be quite common [Nelson, et al. 2012].  Consequently, sufficient sample size and sequence content 
could yield a computationally burdensome quantity of RVs for the L-BRI method.  An illustrative example of 
potentially high RV dimensionality is a targeted sequencing study of the DISC1 locus investigating association with 
psychiatric traits [Thomson, et al. 2013], which identified over 2000 validated RVs (MAF < 1%) across the region 
of interest.  Moreover, most sequencing studies are under-powered for gene-based analyses, prompting multi-genic 
analyses that aggregate rare variants across related genes in a given pathway[Wu and Zhi 2013].  Targeted analysis 
of multiple genes within a gene set could yield similarly extreme quantities of RVs.  These applications may not be 
tenable for the L-BRI or similar approaches without application of strict exclusion criteria that could inadvertently 
filter out causal variation. 
An alternative strategy to handling high dimensional rare variant analysis would be to apply Bayesian 
variable selection in a post-hoc fashion to identify potential causal variation driving an association finding from 
frequentist testing.  One reformulation of the BRI approach would be to instead utilize the probit link function for 
the generalized linear model in combination with alternative MH algorithms that permit effective exploration of the 
model space.  A key advantage of the Bayesian probit regression model is that closed forms of the full conditional 
distributions exist for appropriately selected conjugate priors using data augmentation techniques [Tanner and Wing 
1987], resulting in efficient Gibbs sampling.  The use of probit regression with Bayesian variable selection methods 
for high-dimensional modeling has been demonstrated to be quite powerful in the analysis of gene expression 
[Baragatti 2011; Lee, et al. 2003; Leon-Novelo, et al. 2012; Yang and Song 2010], capable of simultaneous 
consideration of hundreds to thousands of probesets.  The utility of the probit regression approach relative to logistic 
regression for variant analysis in case-control sequencing studies was recently demonstrated by Kang et al. [Kang, et 
al. 2014]. 
Here we propose a fully Bayesian probit regression BRI (P-BRI) method for detection of individual RV 
risk associations and define strategies for instances of high variant dimensionality.  We outline the basic sampling 
algorithm, which is an adaptation of existing Bayesian variable selection procedures for probit regression.  We then 
evaluate the power of our approach at detecting causal rare variants via simulation studies, detailing sensitivity and 
specificity under varying conditions against L-BRI, as well as apply P-BRI to high dimensional variant scenarios.  
To illustrate our method using real data, we apply our P-BRI approach to a prostate cancer (PC) case-control whole-
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exome sequencing (WES) analysis of the previously detected rare variant pathway associations.  Finally, we discuss 
the advantages of our approach and outline extensions and future research directions. 
METHODS 
Model definition 
Consider a case-control rare variation association study with 𝑁𝑁 subjects consisting of 𝑁𝑁𝐷𝐷 cases and 𝑁𝑁𝐶𝐶  
controls, and let 𝒀𝒀 be an 𝑁𝑁 × 1 vector of corresponding binary responses indicating affected status, such that 𝑌𝑌𝑖𝑖 = 1 
if the 𝑖𝑖𝑡𝑡ℎ subject is a case and  𝑌𝑌𝑖𝑖 = 0 if a control.  Let 𝒁𝒁 be an 𝑁𝑁 × 𝑝𝑝 RV genotype matrix, where 𝑧𝑧𝑖𝑖𝑖𝑖 ≡ 𝒁𝒁[𝑖𝑖, 𝑗𝑗] 
represents the minor allele count for subject 𝑖𝑖 at RV position 𝑗𝑗 for 𝑗𝑗 = 1, … 𝑝𝑝.  We also define the 𝑁𝑁 × 𝑞𝑞 design 
matrix 𝑿𝑿 consisting of 𝑞𝑞 additional adjustment covariates, such as age or gender.  In general, it is assumed that the 
proportion of truly causal RVs in 𝒁𝒁 is relatively small and that some form of model selection is desired to identify a 
subset of the total RVs that are associated with the trait of interest.  For our approach we apply variable selection on 
the set of RVs in 𝒁𝒁 to characterize an RV load defined by the selected RVs.  As such, each possible model 𝓜𝓜𝜸𝜸 
within the model space 𝓜𝓜 can be characterized through a variable inclusion vector 𝜸𝜸, a 𝑝𝑝 × 1 vector of indicators 
such that 𝛾𝛾𝑖𝑖 = 1 denotes that the 𝑗𝑗𝑡𝑡ℎ RV is included in the aggregation measure, yielding 2𝑝𝑝 total possible models.  
For even moderate values of 𝑝𝑝, enumeration of all 2𝑝𝑝models 𝓜𝓜𝜸𝜸 ∈𝓜𝓜 is not feasible. 
To account for the effects of RVs on disease risk, we apply a risk index approach that considers the 
aggregate effect of multiple RVs by the collapsed measure 𝑧𝑧𝛾𝛾,𝑖𝑖 = 𝒁𝒁𝒊𝒊′𝜸𝜸, where 𝒁𝒁𝒊𝒊 is a column vector corresponding to 
the 𝑖𝑖𝑡𝑡ℎ row of 𝒁𝒁.  The scalar quantity 𝑧𝑧𝛾𝛾,𝑖𝑖 is the summation of minor alleles over the selected RVs in the model for 
subject 𝑖𝑖 and indicates the subject-wise RV burden, and we denote 𝒁𝒁𝜸𝜸 = �𝑧𝑧𝛾𝛾,1, … , 𝑧𝑧𝛾𝛾,𝑁𝑁�′.  We define the binary 
regression model, such that Pr�𝑌𝑌𝑖𝑖 = 1�𝑿𝑿𝑖𝑖 ,𝑍𝑍𝛾𝛾,𝑖𝑖� = 𝑔𝑔−1(𝜂𝜂𝑖𝑖) 
𝜂𝜂𝑖𝑖 = 𝑿𝑿𝑖𝑖′𝜷𝜷 +  𝑧𝑧𝛾𝛾,𝑖𝑖𝛽𝛽𝛾𝛾 
where 𝑔𝑔(𝜇𝜇) is a link function and 𝜂𝜂𝑖𝑖 denotes the linear predictor.  For our approach, we select the probit link, such 
that 𝑔𝑔−1(𝜇𝜇) = Φ(𝜇𝜇), where Φ(𝜇𝜇) represents the standard Gaussian cumulative probability distribution function.  
The model likelihood can then be written as 
∏ [Φ(𝜂𝜂𝑖𝑖)]𝑦𝑦𝑖𝑖[1 − 𝜙𝜙(𝜂𝜂𝑖𝑖)]1−𝑦𝑦𝑖𝑖𝑖𝑖 , 
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which does not initially provide analytical solutions for the model parameter posteriors.   However, Albert and Chib 
[Albert and Chib 1993] proposed a data augmentation solution to computing probit regression posterior distributions 
by introducing the additional vector of independent latent variables 𝒀𝒀� corresponding to 𝒀𝒀, such that  
𝑌𝑌𝑖𝑖 = �1 𝑖𝑖𝑖𝑖 𝑌𝑌𝚤𝚤� > 0 0 𝑖𝑖𝑖𝑖 𝑌𝑌𝚤𝚤� ≤ 0  
and 
𝑌𝑌𝚤𝚤�|𝑿𝑿𝒊𝒊,𝑍𝑍𝛾𝛾,𝑖𝑖  ~ 𝒩𝒩�𝑿𝑿𝑖𝑖′𝜷𝜷 +  𝑍𝑍𝛾𝛾,𝑖𝑖𝛽𝛽𝛾𝛾 , 1� 
where 𝒩𝒩(𝜇𝜇,𝜎𝜎2) indicates a Gaussian distribution with mean 𝜇𝜇 and variance 𝜎𝜎2.  Thus, the observed dichotomous 
variable 𝒀𝒀 is indicative of the sign of the latent random variable 𝒀𝒀�, which is modeled via linear regression with fixed 
variance. 
Prior distributions 
We opt for traditional conjugate priors where applicable in order to attain full conditional distributions.  We 
first define the prior distribution on the vector of design covariate parameters, 𝜷𝜷, to be a 𝑞𝑞-dimensional multivariate 
Gaussian distribution such that 
𝜷𝜷 ~ 𝒩𝒩𝑞𝑞(𝟎𝟎,𝑁𝑁(𝑿𝑿′𝑿𝑿)−1)  
which is a conventional g-prior distribution[Zellner 1983] in probit regression coefficients for blocked Gibbs 
sampling.  We similarly place a standard Gaussian prior on the BRI coefficient 𝛽𝛽𝛾𝛾, such that 𝛽𝛽𝛾𝛾  ~ 𝒩𝒩(0,1). 
We specify the prior probability of a given model 𝓜𝓜𝜸𝜸 ∈𝓜𝓜, Pr�𝓜𝓜𝜸𝜸� through the individual variable prior 
inclusion probabilities Pr�𝛾𝛾𝑖𝑖 = 1� = 𝜋𝜋𝑖𝑖 , such that Pr�𝓜𝓜𝜸𝜸� = ∏ 𝜋𝜋𝑖𝑖𝛾𝛾𝑗𝑗�1 − 𝜋𝜋𝑖𝑖�1−𝛾𝛾𝑗𝑗𝑟𝑟𝑖𝑖=1 .  We define the model 
probability in this fashion via the assumption that the probabilities that given RVs are included in the model are 
independent, since low linkage disequilibrium is expected among RV sites [Pritchard 2001].  The vector  𝝅𝝅 =
�𝜋𝜋1, … ,𝜋𝜋𝑝𝑝�′ can either reflect no differential prior belief of inclusion, such that 𝜋𝜋1 = ⋯ = 𝜋𝜋𝑝𝑝 = 𝜋𝜋, or may differ 
based upon available functional data that informs potential RV functionality in relation to the trait of interest.  
Similar to Quintana et al. [Quintana, et al. 2011], we specify the default prior on 𝛾𝛾𝑖𝑖 to be 𝜋𝜋𝑖𝑖 = �1 − �12�1𝑝𝑝�, such that 
the prior probability of the global null model Pr(𝓜𝓜𝟎𝟎) =  Pr�𝜸𝜸 = 𝟎𝟎𝒑𝒑×𝟏𝟏�  = ∏ �1 − 𝜋𝜋𝑖𝑖�𝑖𝑖 = 12 to account for the 
potential of a Type I error as well as render the models equitable in this regard. 
Bayesian sampling algorithm 
8 
 
To obtain estimates of the posterior quantities of interest, we apply a Markov Chain Monte Carlo (MCMC) 
approach [Hastings 1970], whereby samples from the respective posterior distributions of the model parameters are 
iteratively drawn using Gibbs sampling (GS) and MH methods.  To define our sampler, we first must characterize 
the full conditional distributions of the model parameters, which include 𝑖𝑖�𝒀𝒀��𝒀𝒀,𝜷𝜷,𝛽𝛽𝛾𝛾,𝜸𝜸�, 𝑖𝑖�𝜷𝜷�𝒀𝒀�,𝛽𝛽𝛾𝛾 ,𝜸𝜸�, 
𝑖𝑖�𝛽𝛽𝛾𝛾�𝒀𝒀�,𝜷𝜷,𝜸𝜸�, and 𝑖𝑖(𝜸𝜸|𝒀𝒀�,𝜷𝜷,𝜷𝜷𝜸𝜸).  The full conditional distributions for the first three can easily be derived, such 
that 
• 𝑌𝑌𝚤𝚤�|𝑌𝑌𝑖𝑖 = 1 ~ 𝒩𝒩�𝑿𝑿𝑖𝑖′𝜷𝜷 + 𝑍𝑍𝛾𝛾,𝑖𝑖𝛽𝛽𝛾𝛾 , 1�  left truncated at 0  
• 𝑌𝑌𝚤𝚤�|𝑌𝑌𝑖𝑖 = 0 ~ 𝒩𝒩�𝑿𝑿𝑖𝑖′𝜷𝜷 + 𝑍𝑍𝛾𝛾,𝑖𝑖𝛽𝛽𝛾𝛾 , 1�  right truncated at 0  
• 𝜷𝜷|𝒀𝒀�,𝛼𝛼,𝜸𝜸 ~ 𝒩𝒩(𝑽𝑽𝜷𝜷𝑿𝑿′�𝒀𝒀� − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾  �,𝑽𝑽𝜷𝜷)   where  𝑽𝑽𝜷𝜷 = 𝑁𝑁𝑁𝑁+1 (𝑿𝑿′𝑿𝑿)−1 
• 𝛽𝛽𝛾𝛾|𝒀𝒀�,𝜷𝜷,𝜸𝜸 ~ 𝒩𝒩�𝑣𝑣𝛾𝛾𝒁𝒁𝜸𝜸′ �𝒀𝒀� − 𝑿𝑿𝜷𝜷�, 𝑣𝑣𝛾𝛾�  where 𝑣𝑣𝛾𝛾 = 1𝜎𝜎𝛽𝛽−2+𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸 
Since these distributions are properly defined, GS methods can be used for iterative updating.  However, under our 
BMU procedure, the full conditional distribution of 𝜸𝜸 cannot be directly simulated easily, requiring a Metropolis-
within-Gibbs approach.  To sample from the distribution of 𝜸𝜸, we adopt a marginalization strategy [Liu 1994], 
which is based upon the integrated distribution of the full conditional of 𝜸𝜸 over 𝛽𝛽𝛾𝛾, 𝑖𝑖�𝜸𝜸�𝒀𝒀�,𝜷𝜷�.  It can be shown 
using Bayesian linear model theory that 𝑖𝑖�𝜸𝜸�𝒀𝒀�,𝜷𝜷� is proportional to 
exp�− 12��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′ �𝑰𝑰𝑵𝑵 − 𝒁𝒁𝜸𝜸𝒁𝒁𝜸𝜸′𝜎𝜎𝛽𝛽−2 + 𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸� �𝒀𝒀� − 𝑿𝑿𝜷𝜷��� × �𝜋𝜋𝑖𝑖𝛾𝛾𝑗𝑗�1 − 𝜋𝜋𝑖𝑖�1−𝛾𝛾𝑗𝑗𝑝𝑝𝑖𝑖=1  
which we use to define a MH algorithm for updating 𝜸𝜸, directly followed by simulation of 𝛽𝛽𝛾𝛾 from its full 
conditional distribution. 
There are a number of options for proposing new values of 𝜸𝜸 in the MH step of the MCMC sampler.  
Quintana et al. [Quintana, et al. 2011] elected a single-step addition/deletion MH algorithm for model selection in L-
BRI, whereby the proposed vector 𝜸𝜸 is generated by switching the binary value of a randomly chosen variable 
inclusion indicator 𝛾𝛾𝑖𝑖.  However, in instances of higher RV dimensionality, this approach requires a prohibitively 
large number of iterations to adequately explore the model space 𝓜𝓜, resulting in relatively poor mixing.   In 
contrast, updating each 𝛾𝛾𝑖𝑖 in a component-wise fashion can significantly improve mixing and convergence and may 
result in overall better performance [Johnson, et al. 2013].  Consequently, we apply a component-wise multistep MH 
algorithm, similar to that applied by Lee et al.[Lee, et al. 2014] for imaging data, that iteratively updates each 
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element in 𝜸𝜸. This is conducted in a modified metropolised Gibbs framework, such that the proposal for 𝛾𝛾𝑖𝑖is always 
the opposite of the current state, yielding more efficient mixing[Liu 1996].  The unique formulation of the risk index 
as a product of a fixed design matrix 𝒁𝒁 and variable inclusion vector 𝜸𝜸 permits computationally efficient 
component-wise MH updating, which is generally infeasible for high dimensional problems.  At each iteration of the 
MCMC algorithm we randomize the updating order of MH step for 𝜸𝜸, and convergence to the stationary distribution 
may be checked by running multiple chains from different initial values and comparing posterior samples. 
Given that the defined prior on the BRI parameter 𝛽𝛽𝛾𝛾 has positive support over the entire real line, it is 
possible for the sampler to draw negative values of 𝛽𝛽𝛾𝛾 despite it characterizing risk.  One simple solution is to 
constrain the prior distribution to the positive real line by using a truncated normal prior.  By Gelfand et al. 
[Gelfand, et al. 1992], we can accommodate this prior by adding a rejection step to the Gibbs sampler for 𝛽𝛽𝛾𝛾, 
accepting new draws of 𝛽𝛽𝛾𝛾, 𝛽𝛽𝛾𝛾
(⋆), only if 𝛽𝛽𝛾𝛾(⋆) > 0.  
Posterior measures of interest 
Conditional on evidence against the global null model ℳ0 (e.g., from a previously conducted test), a 
primary motivation is identifying an interesting subset of variants associated with the disease of interest for follow-
up analyses.  In the case of variable selection problems, the marginal posterior probabilities of inclusion are useful 
for such inference.  Denote 𝜁𝜁𝑖𝑖 = Pr�𝛾𝛾𝑖𝑖 = 1�𝒀𝒀� to be the marginal posterior probability of inclusion for 𝑗𝑗𝑡𝑡ℎ RV in 𝒁𝒁.  
Quintana et al. [Quintana, et al. 2011] derive the marginal BFs to isolate RVs that may be driving an association, 
such that 
𝐵𝐵𝐵𝐵�𝛾𝛾𝑖𝑖 = 1: 𝛾𝛾𝑖𝑖 = 0� = Pr�𝛾𝛾𝑖𝑖 = 1�𝒀𝒀�Pr�𝛾𝛾𝑖𝑖 = 0�𝒀𝒀� × Pr�𝛾𝛾𝑖𝑖 = 0�Pr�𝛾𝛾𝑖𝑖 = 1� = 𝜁𝜁𝑖𝑖1 − 𝜁𝜁𝑖𝑖 × 1 − 𝜋𝜋𝑖𝑖𝜋𝜋𝑖𝑖  
We estimate ζ𝑖𝑖in a Monte Carlo fashion from the 𝑇𝑇 posterior samples of 𝜸𝜸, such ζ̂𝑖𝑖 = ∑ 𝛾𝛾𝑗𝑗(𝑡𝑡)𝑟𝑟𝑇𝑇 .  Decisions of relative 
importance of each RV can then be made with respect to common thresholds (e.g., >10 or 31.6) defined by Jeffreys’ 
grades of evidence [Jeffreys 1961] using these marginal BFs.   
Simulations 
To evaluate the performance of P-BRI at identifying individual risk associated RVs, we considered a 
hypothetical case-control genetic association study with 𝑁𝑁 = 1000 total subjects (𝑁𝑁𝐷𝐷 = 𝑁𝑁𝐶𝐶).  To simulate the RV 
genotype data conditional on disease status, we employed the model developed by Li and Leal [Li and Leal 2008] 
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and algorithmically defined by Zhou et al. [Zhou, et al. 2010].  This model is based upon the conditional Poisson-
binomial whereby any of the 𝑣𝑣 risk RVs can independently cause the disease status, defined though the MAFs, 
prevalence, and relative risks of RVs.  The MAFs for all RVs were randomly generated uniformly on the interval (0.005,0.01), and all simulated RVs that resulted in an empirical MAF of zero were excluded from analysis.  
Prevalence was fixed at 0.01 and no additional covariates were included in the simulation model.  Simulations under 
the null (i.e., no causal variation) simply involved random assignment of case-control status to randomly generated 
RV genotype vectors. 
We first compared the performance of the P-BRI relative to the original L-BRI at detecting causal RVs in 
scenarios that were computationally reasonable for either method, fixing 𝑝𝑝 = 50.  Software implementation of the 
L-BRI method is available via the R package BVS, which we applied under default settings unless otherwise noted.  
For simulations involving causal variation, we considered the quantity of truly causal RVs, 𝑣𝑣, to range from 5 to 15, 
and applied both the P-BRI and L-BRI methods to detect the associated RVs.   All causal RVs were attributed a 
relative risk (RR) of 1.5, 2.5, or 5, with all remaining RVs being neutral (RR = 1).  Convergence of the L-BRI was 
evaluated by running two parallel chains and comparing output marginal BFs, as per the method’s documentation, 
with convergence defined by the root mean square error between the two sets of BFs to be < 1.  To evaluate 
convergence of P-BRI, the Gelman-Rubin diagnostic was applied to MCMC posterior samples of 𝛽𝛽𝛾𝛾 for two parallel 
chains with different starting values, with convergence declared if the upper 95% confidence limit was < 2.  For the 
P-BRI method we sampled a total of 30,000 iterations, treating the first 15,000 as a burn-in, while for the L-BRI 
method we sampled 100,000 iterations and treated the first 50,000 as a burn-in.  If convergence was not achieved at 
these iteration counts additional posterior samples were drawn until convergence criteria were met.   Marginal BFs 
were also computed for P-BRI in order to compare the relative false positive (FPR) and true positive rates (TPR) 
based upon detection of causal variant status across all simulation iterations (50 × 500 = 25000 total variants).  For 
P-BRI, instances where RVs had corresponding posterior inclusion probabilities (PIPs) estimates 𝜁𝜁𝑖𝑖 = 1 were 
adjusted to 𝜁𝜁𝑖𝑖 = 𝑇𝑇−1𝑇𝑇  to avoid division by zero in the marginal BF.  For purposes of comparing performance between 
L-BRI and P-BRI relative to TPR and FPR, we computed bootstrapped 95% confidence intervals on these metrics 
and/or their differential across methods using the R package fbroc, based upon 1000 bootstrap samples. 
To additionally examine the performance of P-BRI under high RV dimensionality, we increased the total 
RV counts to 𝑝𝑝 = 500 and 𝑝𝑝 = 1000 and fixed the number of true deleterious RVs to 𝑣𝑣 = 25, such that the causal 
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RV proportions were 5.0% (𝑝𝑝 = 500) and 2.5% (𝑝𝑝 = 1000), respectively.  Given the larger quantity of RVs under 
simultaneous consideration, we focused on identification of larger effect sizes and examined performance for RRs of 
2.5, 5, and 10 for causal RVs.  For these applications, the first 15,000 MCMC samples were discarded as a burn-in, 
resulting in a posterior sample size of 15,000. 
Data Application:  Prostate Cancer Risk 
A whole-exome sequencing study of men with prostate cancer was conducted by the International 
Consortium of Prostate Cancer Genetics (ICPCG). The ICPCG has identified and sampled the most informative 
high-risk PC pedigrees known throughout the world. With the goal of identifying PC susceptibility loci utilizing this 
extraordinary collection of families, WES was performed on 539 familial cases of PC derived from 366 families all 
having at least three affected men with PC: 257 cases from 84 families (the majority having three sequenced/family) 
and 282 singleton cases. Whole-exome sequencing was performed using the Agilent 50Mb SureSelect Human All 
Exon chip or the Agilent SureSelect V4+UTR kit. Bioinformatics analysis was performed using GenomeGPS, a 
comprehensive analysis pipeline developed at Mayo Clinic which performs alignment using Novoalign (v.07.13), 
realignment and recalibration using the Genome Analysis Tool Kit (GATK,v3.3), germline single nucleotide and 
small insertion/deletion variant calling using GATK HaplotypeCaller, and Variant quality score recalibration 
(VQSR), following GATK best practices v3 [DePristo, et al. 2011; McKenna, et al. 2010; Van der Auwera, et al. 
2013].  Population-based controls were selected from samples that were sequenced at Mayo Clinic using similar 
library preparation and sequencing to the cases.  We identified 494 samples from four studies which met our 
inclusion criteria (germline sequencing using Agilent V2 or V4+UTR capture and with initial alignment performed 
using the same version of Novoalign.  Samples included 89 unselected samples from the Mayo Clinic Community 
Biobank, 355 samples from two studies of cardiovascular phenotypes and 50 samples from a study of neuropathy.  
All samples were re-processed using the bioinformatics pipeline described above and underwent the same stringent 
quality control analyses.   
We conducted a pathway-directed RV case-control study (see Supplemental Methods for details) to 
evaluate the role of RVs in risk of PC using 860 gene-set definitions from KEGG [Kanehisa 2002] and Reactome 
[Joshi-Tope, et al. 2005].   For our purposes, we restricted our analyses to unrelated subjects by randomly selecting 
single individuals from pedigrees with multiple sequenced subjects.  After sample exclusions for quality control or 
relatedness, a total of 333 cases and 349 controls remained.   In our analyses, we identified multiple highly 
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overlapping gene-sets related to the Lands cycle (Reactome IDs R-HSA-1482922.1, R-HSA-1483226.1, R-HSA-
1482788.1, R-HSA-1482839.1, R-HSA-1482925.1) to be significantly associated (P <5.8E-05) using SKAT-O[Lee, 
et al. 2012] and burden-based testing.  The Lands cycle is involved in the acyl-chain remodeling of a variety of 
phospholipids, and the union of the associated pathways constitutes 26 genes involving 438 unique observed 
variants with empirical MAF < 0.05.  To investigate which RVs may be driving the association, we applied the P-
BRI approach to the data, including additional covariate adjustment for WES capture kit and five leading principal 
components derived from the complete genetic data.  Similar posterior sampling procedures that were used in the 
simulations were applied and no additional information was used to alter the priors on 𝜸𝜸. 
RESULTS 
Simulation Analysis 
The TPRs for RV associations declared at a marginal BF threshold of BF ≥ 10 are presented in Table I.  Overall, we 
observed higher TPR as well as FPRs for L-BRI relative to P-BRI, indicating marginal BFs to be larger in general 
for the L-BRI approach and rendering performance comparisons difficult.  When evaluating TPRs at a fixed FPR of 
0.01 (Table II), we noted comparable performance.  We additionally observed reduced TPR at fixed RR effect sizes 
as the proportion of causal variants increased, regardless of method.  This is likely due to the fact that models 
encompassing a larger number of causal variants are less likely under the default prior distribution on the model 
space 𝓜𝓜.  In general, performance was comparable between the two approaches, with P-BRI tending to perform 
better under conditions of lower effect size and smaller proportion of causal variants and L-BRI under large effect 
sizes and higher causal variant proportion. 
Marginal TPR and FPR results at BF thresholds of 10 and 31.6 for the high RV dimensionality simulations 
are presented in Table III.  We observed similar patterns of performance with respect to underlying RR and causal 
variant proportions as observed in the low RV count simulations, with higher global TPRs for 𝑝𝑝 = 500 relative to 
𝑝𝑝 = 1000 for a fixed causal variant effect size.  Marginal RV detection evaluated by TPR and FPR was comparable 
across differing total number of evaluated variants at a fixed BF threshold, with increasing TPR at higher effect sizes 
with the FPR remaining relatively fixed. 
The above simulation results do not take into account the likely high degree of multiple testing that would 
likely occur prior to post-hoc evaluation, as the simulations only consider the case where true causal variation is 
present.   Consequently, false positive rates may be higher than reported, depending upon how Type I error was 
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controlled at the first stage of testing.  To evaluate the behavior of P-BRI under false positive testing results, we 
conducted an additional 500 simulations for each of the high variant dimensionality conditions where none of the 
simulated variants were associated with case/control status.  At a BF threshold of 10, variant-level false positive 
rates were commensurate with those reported in Table III (0.012 for 𝑝𝑝 =  500; 0.013 for 𝑝𝑝 =  1000). 
Data Application 
The marginal BFs for the 438 RVs analyzed in the PC risk analysis are presented in Figure 1.  A total of four 
variants in three separate genes corresponded to a BF >10 (Table IV), including a splice-site variant in gene 
PLA2G4F (hg19 chr15:42448635A→T) with a corresponding marginal BF of 2787.7 and PIP of 0.815, occurring in 
19 cases but only one control.  Both PLA2G4D and PLA2G4F encode proteins that selectively hydrolyze 
glycerophospholipids, and dysregulation of lipid metabolism has been noted in many cancers[Huang and Freter 
2015]. 
To evaluate the MCMC mixing for the data application, we computed the model mutation rate as the 
proportion of posterior samples that resulted in model state transitions (77.5%). Computational runtime for the full 
30,000 iterations was approximately 20 minutes.  Similar application of L-BRI resulted in only 188 accepted model 
transitions (mutation rate = 1.25%) for the same number of iterations.  After 100,000 iterations (~1 hour runtime) for 
two independent runs with a 50,000 burn-in, examination of the marginal BF output from L-BRI still indicated lack 
of convergence. 
DISCUSSION 
In this paper, we have presented a regression-based Bayesian variable selection strategy for post-hoc 
analysis of aggregative RV associations in disease risk via a reformulation of the BRI method for case-control RV 
association analysis.   By modeling the probability of affected status using a probit link function, in contrast to a 
logistic regression approach, we have demonstrated the method to be feasible for high dimensional applications.  We 
have also proposed a component-wise MH algorithm for updating the variable inclusion vector 𝜸𝜸, which results in 
rapid exploration of the model space.  Our simulation results comparing L-BRI and P-BRI for moderate RV counts 
indicate that their ability to detect causal RVs is comparable for a variety of conditions, while P-BRI was also 
capable of detecting causal variation under very high RV dimensionality.  This renders P-BRI a powerful method for 
dense post-hoc RV association analyses, as evidenced by both our large-scale simulations and our PC risk analysis 
of 438 RVs within genes involved in the Lands Cycle.  The application of our approach indicates the significant 
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associations previously detected by pathway-based analyses may be driven by variants within three phospholipase 
genes and additional targeted sequencing of these genes may be warranted in future research. 
From a computational perspective, our probit approach benefits from a multi-step MH algorithm for 
updating variable inclusion vector 𝜸𝜸.  Execution runtimes for P-BRI in our simulation study under conditions where 
𝑝𝑝 = 50 and 𝑁𝑁 = 1000 averaged 6.2 minutes, while runtimes for our larger simulations where 𝑝𝑝 = 1000 and 
𝑁𝑁 = 1000 at 30,000 iterations were approximately 75 minutes on average.  The latter analyses were not feasible for 
L-BRI in our simulations due to the high model space dimensionality and single-step updating of 𝜸𝜸. These timings 
are based upon working code written in the R statistical language and executed on a modern workstation equipped 
with a Quad-Core AMD Opteron™ Processor and 16 Gb of RAM.  We anticipate that computational burden for the 
P-BRI method may be further reduced substantially with alternative BVS methods, such as objective Bayes model 
selection [Leon-Novelo, et al. 2012] and particle stochastic search [Shi and Dunson 2011] approaches, as well as 
implementation of parts of the current MCMC algorithm in more computationally efficient computer languages such 
as C++. 
A simplifying assumption of risk index methods in general is that each included RV contributes an equal 
effect to the RV burden, or rather that it models the mean effect of the selected RVs.  While this assumption permits 
efficient sampling, it may not accurately reflect the effects of the individual RV associations.  It is possible to utilize 
existing structural definitions, such as genes or exons, as a grouping mechanism and assign separate burden-based 
parameters, although careful consideration is necessary to avoid singular design matrices if the number of included 
elements exceeds the sample size.  If protective RV’s are present, they would not be appropriately modeled by our 
approach.  However, the P-BRI method could be simply modified by increasing the support of 𝜸𝜸 to include negative 
indicators, as in the MixBRI approach by Quintana et al. [Quintana, et al. 2011].   
Although the P-BRI method permits efficient exploration of high-dimensional model spaces, alternative 
MH algorithms for sampling from the model space 𝓜𝓜 may be useful in extreme scenarios where the RV 
dimensionality renders the component-wise MH algorithm computationally infeasible.  One approach is to consider 
a subset of the model space 𝓜𝓜, 𝓜𝓜𝒃𝒃, by defining the MH transition kernel such that the number of included RVs in 
any model 𝓜𝓜𝜸𝜸 ∈𝓜𝓜𝒃𝒃 is invariant and equal to an a priori defined quantity 𝑏𝑏.  This approach is comparable to the 
MCMC algorithm outlined in Baragatti [Baragatti 2011] and preliminary simulations indicate feasibility for P-BRI 
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with 𝑝𝑝 ≥ 10,000, although further work is necessary to formally develop these methods.  Adaptive algorithms 
designed for high-dimensional sampling in GWAS may also be of utility[Peltola, et al. 2012]. 
 There are a variety of promising extensions from our development of the P-BRI method for post-hoc RV 
analysis.  An added benefit of this work is that application to quantitative traits is trivial, since the algorithms are 
already in place through the latent variable 𝒀𝒀�, although variational Bayesian methods have previously demonstrated 
high computational efficiency in this area[Logsdon, et al. 2014]. We could also extend the regression procedure to 
include common variants in the model selection for a comprehensive association analysis, as well as easily adopt the 
integrative variable selection procedures in Quintana et al. [Quintana and Conti 2013] for informed model selection 
based upon existing variant annotation.   Finally, we are actively evaluating methods to estimate global null model 
posterior probabilities using sampling procedures implemented by Liang et al.[Liang and Xiong 2013] for 
association inference, as well as integrating P-BRI methods with curated pathway databases to facilitate genome-
wide exploratory rare variant gene-set analysis. 
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SUPPLEMENTARY METHODS 
Defining component-wise MH algorithm 
Note that 
𝑖𝑖�𝒀𝒀��𝜸𝜸,𝜷𝜷� = ∫ 𝑖𝑖�𝒀𝒀��𝜸𝜸,𝜷𝜷,𝛽𝛽𝛾𝛾�𝑖𝑖�𝛽𝛽𝛾𝛾�𝑑𝑑𝛽𝛽𝛾𝛾∞−∞ ∝ ∫ exp �− 12 �𝒀𝒀� − 𝑿𝑿𝜷𝜷 − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾�′�𝒀𝒀� − 𝑿𝑿𝜷𝜷 − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾�� 𝑖𝑖�𝛽𝛽𝛾𝛾�𝑑𝑑𝛽𝛽𝛾𝛾∞−∞ . 
 
Note expansion of the term �𝒀𝒀� − 𝑿𝑿𝜷𝜷 − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾�
′
𝑰𝑰𝑵𝑵
−𝟏𝟏�𝒀𝒀� − 𝑿𝑿𝜷𝜷 − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾� yields 
�𝒀𝒀� − 𝑿𝑿𝜷𝜷 − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾�
′
�𝒀𝒀� − 𝑿𝑿𝜷𝜷 − 𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾� = �𝒀𝒀� − 𝑿𝑿𝜷𝜷�′�𝒀𝒀� − 𝑿𝑿𝜷𝜷� − �𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾�′�𝒀𝒀� − 𝑿𝑿𝜷𝜷� − �𝒀𝒀� − 𝑿𝑿𝜷𝜷�′�𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾� +
�𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾�
′
�𝒁𝒁𝜸𝜸𝛽𝛽𝛾𝛾� = �𝒀𝒀� − 𝑿𝑿𝜷𝜷�′�𝒀𝒀� − 𝑿𝑿𝜷𝜷� − 2𝛽𝛽𝛾𝛾��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸� + 𝛽𝛽𝛾𝛾2𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸. 
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From the above, we can rewrite 𝑖𝑖�𝒀𝒀��𝜸𝜸,𝜷𝜷� as proportional to 
exp �− 1
2
�𝒀𝒀� − 𝑿𝑿𝜷𝜷�
′
�𝒀𝒀� − 𝑿𝑿𝜷𝜷�� × ∫ exp �− 1
2
�𝛽𝛽𝛾𝛾
2𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸 − 2𝛽𝛽𝛾𝛾��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸��� 𝑖𝑖�𝛽𝛽𝛾𝛾�𝑑𝑑𝛽𝛽𝛾𝛾∞−∞ . 
Given that the prior distribution on 𝛽𝛽𝛾𝛾 is 𝑖𝑖�𝛽𝛽𝛾𝛾� = 1
�2𝜋𝜋𝜎𝜎𝛽𝛽
exp �− 𝛽𝛽𝛾𝛾2
2𝜎𝜎𝛽𝛽
2�, it follows that  
∫ exp �− 1
2
�𝛽𝛽𝛾𝛾
2𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸  − 2𝛽𝛽𝛾𝛾��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸��� 𝑖𝑖�𝛽𝛽𝛾𝛾�𝑑𝑑𝛽𝛽𝛾𝛾∞−∞ ∝ ∫ exp�− 12 �𝛽𝛽𝛾𝛾2𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸 − 2𝛽𝛽𝛾𝛾��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸� +∞−∞
1
𝜎𝜎𝛽𝛽
2 𝛽𝛽𝛾𝛾
2�� 𝑑𝑑𝛽𝛽𝛾𝛾. 
We can complete the square in the exponential term, such that  
𝛽𝛽𝛾𝛾
2𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸 − 2𝛽𝛽𝛾𝛾��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸� + 𝛽𝛽𝛾𝛾2 = �𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸 + 𝜎𝜎𝛽𝛽−2� �𝛽𝛽𝛾𝛾 − �𝒀𝒀�−𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸�𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸+𝜎𝜎𝛽𝛽−2�� − �𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸 + 𝜎𝜎𝛽𝛽−2� � �𝒀𝒀�−𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸�𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸+𝜎𝜎𝛽𝛽−2��2. 
Given the presence of the Gaussian kernel, it follows that 
∫ exp �− 1
2
�𝛽𝛽𝛾𝛾
2𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸 − 2𝛽𝛽𝛾𝛾��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸� + 𝛽𝛽𝛾𝛾2�� 𝑑𝑑𝛽𝛽𝛾𝛾∞−∞ ∝ exp�12 ��𝒀𝒀�−𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸�𝟐𝟐 �𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸+𝜎𝜎𝛽𝛽−2� �. 
Note the following 
��𝒀𝒀�−𝑿𝑿𝜷𝜷�
′
𝒁𝒁𝜸𝜸�
𝟐𝟐 
�𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸+𝜎𝜎𝛽𝛽
−2�
= 1
𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸+𝜎𝜎𝛽𝛽
−2 �𝒀𝒀� − 𝑿𝑿𝜷𝜷�
′
𝒁𝒁𝜸𝜸𝒁𝒁𝜸𝜸
′  (𝒀𝒀� − 𝑿𝑿𝜷𝜷). 
It then follows that 
𝑖𝑖�𝒀𝒀��𝜸𝜸,𝜷𝜷� ∝ exp�− 1
2
��𝒀𝒀� − 𝑿𝑿𝜷𝜷�
′
�𝑰𝑰𝑵𝑵 −
𝒁𝒁𝜸𝜸𝒁𝒁𝜸𝜸
′
�𝒁𝒁𝜸𝜸
′ 𝒁𝒁𝜸𝜸+𝜎𝜎𝛽𝛽
−2�
� �𝒀𝒀� − 𝑿𝑿𝜷𝜷���. 
Then,  
𝑖𝑖�𝜸𝜸�𝒀𝒀�,𝜷𝜷� ∝ 𝑖𝑖�𝒀𝒀��𝜸𝜸,𝜷𝜷�𝑖𝑖(𝜸𝜸) ∝ exp�− 12��𝒀𝒀� − 𝑿𝑿𝜷𝜷�′ �𝑰𝑰𝑵𝑵 − 𝒁𝒁𝜸𝜸𝒁𝒁𝜸𝜸′�𝒁𝒁𝜸𝜸′ 𝒁𝒁𝜸𝜸 + 𝜎𝜎𝛽𝛽−2�� �𝒀𝒀� − 𝑿𝑿𝜷𝜷��� × �𝜋𝜋𝑖𝑖𝛾𝛾𝑗𝑗�1 − 𝜋𝜋𝑖𝑖�1−𝛾𝛾𝑗𝑗𝑝𝑝𝑖𝑖=1 . 
New values of 𝜸𝜸 are accepted conditional on the current state of 𝜸𝜸 based upon the MH acceptance probability 
function 
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𝜌𝜌�𝜸𝜸(𝑡𝑡),𝜸𝜸(⋆)�
= min
⎝
⎜
⎜
⎜
⎜
⎛𝑒𝑒𝑒𝑒𝑝𝑝�
12� 1�(𝒁𝒁𝜸𝜸(⋆))′𝒁𝒁𝜸𝜸(⋆) + 𝜎𝜎𝛽𝛽−2� �𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸(⋆)�𝒁𝒁𝜸𝜸(⋆)�′�𝒀𝒀� − 𝑿𝑿𝜷𝜷���∏ 𝜋𝜋𝑖𝑖𝛾𝛾𝑗𝑗(⋆)�1 − 𝜋𝜋𝑖𝑖�1−𝛾𝛾𝑗𝑗(⋆)𝑟𝑟𝑖𝑖=1
𝑒𝑒𝑒𝑒𝑝𝑝 �
12� 1�(𝒁𝒁𝜸𝜸(𝑡𝑡))′𝒁𝒁𝜸𝜸(𝑡𝑡) + 𝜎𝜎𝛽𝛽−2� �𝒀𝒀� − 𝑿𝑿𝜷𝜷�′𝒁𝒁𝜸𝜸(𝑡𝑡)(𝒁𝒁𝜸𝜸(𝑡𝑡))′�𝒀𝒀� − 𝑿𝑿𝜷𝜷���∏ 𝜋𝜋𝑖𝑖𝛾𝛾𝑗𝑗(𝑡𝑡)�1 − 𝜋𝜋𝑖𝑖�1−𝛾𝛾𝑗𝑗(𝑡𝑡)𝑟𝑟𝑖𝑖=1
, 1
⎠
⎟
⎟
⎟
⎟
⎞
 
𝜌𝜌�𝜸𝜸(𝑡𝑡),𝜸𝜸(⋆)� = min�exp�12 �𝒀𝒀� − 𝑿𝑿𝜷𝜷�′ � 𝒁𝒁𝜸𝜸(⋆)�𝒁𝒁𝜸𝜸(⋆)�′𝜎𝜎𝛽𝛽−2 + (𝒁𝒁𝜸𝜸(⋆))′(𝒁𝒁𝜸𝜸(⋆)) − 𝒁𝒁𝜸𝜸(𝑡𝑡)�𝒁𝒁𝜸𝜸(𝑡𝑡)�′𝜎𝜎𝛽𝛽−2 + (𝒁𝒁𝜸𝜸(𝑡𝑡))′(𝒁𝒁𝜸𝜸(𝑡𝑡))� �𝒀𝒀�
− 𝑿𝑿𝜷𝜷����
𝜋𝜋𝑖𝑖1 − 𝜋𝜋𝑖𝑖�𝛾𝛾𝑗𝑗(⋆)−𝛾𝛾𝑗𝑗(𝑡𝑡)𝑟𝑟
𝑖𝑖=1
, 1� 
For component-wise updating of 𝜸𝜸, note that 
𝑖𝑖�𝛾𝛾𝑖𝑖�𝒀𝒀�,𝜷𝜷,𝜸𝜸(−𝒋𝒋)� ∝ 𝑖𝑖(𝒀𝒀�|𝜸𝜸,𝜷𝜷) × � 𝜋𝜋𝑗𝑗1−𝜋𝜋𝑗𝑗�𝛾𝛾𝑗𝑗(⋆)−𝛾𝛾𝑗𝑗(𝑡𝑡), 
where 𝜸𝜸(−𝒋𝒋) indicates the vector of  values in 𝜸𝜸 other than 𝛾𝛾𝑖𝑖.  Then 𝜸𝜸(⋆) differs from 𝜸𝜸(𝒕𝒕) at the 𝑗𝑗𝑡𝑡ℎ element, such 
that 𝛾𝛾𝑖𝑖
(⋆) = 1 if 𝛾𝛾𝑖𝑖(𝑡𝑡) = 0 or 𝛾𝛾𝑖𝑖(⋆) = 0 if 𝛾𝛾𝑖𝑖(𝑡𝑡) = 1.  We can reparameterize the acceptance probability with respect to 
𝒁𝒁𝜸𝜸 = 𝒁𝒁𝜸𝜸, such that 
𝒁𝒁𝜸𝜸
(⋆) = 𝒁𝒁𝜸𝜸(𝒕𝒕) ± 𝒁𝒁𝒋𝒋, 
where 𝒁𝒁𝒋𝒋 is the 𝑗𝑗𝑡𝑡ℎ column of 𝒁𝒁 and the sign of the operation (+ or -) is dictated by the current state of 𝛾𝛾𝑖𝑖.  Simplify 
notation by 𝒀𝒀�𝒓𝒓𝒓𝒓𝒓𝒓 = 𝒀𝒀� − 𝑿𝑿𝜷𝜷, and we write 𝜌𝜌�𝛾𝛾𝑖𝑖(𝑡𝑡), 𝛾𝛾𝑖𝑖(⋆)� as 
min�exp�1
2
𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟
′  � �𝒁𝒁𝜸𝜸(𝒕𝒕)±𝒁𝒁𝒋𝒋��𝒁𝒁𝜸𝜸(𝒕𝒕)±𝒁𝒁𝒋𝒋�′
𝜎𝜎𝛽𝛽
−2+�𝒁𝒁𝜸𝜸
(𝒕𝒕)±𝒁𝒁𝒋𝒋�′�𝒁𝒁𝜸𝜸(𝒕𝒕)±𝒁𝒁𝒋𝒋� − �𝒁𝒁𝜸𝜸
(𝒕𝒕)��𝒁𝒁𝜸𝜸(𝒕𝒕)�′
𝜎𝜎𝛽𝛽
−2+�𝒁𝒁𝜸𝜸
(𝒕𝒕)�′�𝒁𝒁𝜸𝜸(𝒕𝒕)��𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟� �
𝜋𝜋𝑗𝑗
1−𝜋𝜋𝑗𝑗
�
𝛾𝛾𝑗𝑗
(⋆)−𝛾𝛾𝑗𝑗(𝑡𝑡) , 1�. 
Define 𝑎𝑎(⋆) = 1
𝜎𝜎𝛽𝛽
−2+�𝒁𝒁𝜸𝜸
(𝒕𝒕)±𝒁𝒁𝒋𝒋�′�𝒁𝒁𝜸𝜸(𝒕𝒕)±𝒁𝒁𝒋𝒋� and 𝑎𝑎(𝑡𝑡) = 1𝜎𝜎𝛽𝛽−2+�𝒁𝒁𝜸𝜸(𝒕𝒕)�′�𝒁𝒁𝜸𝜸(𝒕𝒕)�.  It then follows that 𝜌𝜌�𝛾𝛾𝑖𝑖(𝑡𝑡), 𝛾𝛾𝑖𝑖(⋆)� simplifies to 
min�exp�1
2
 ��𝑎𝑎(⋆) − 𝑎𝑎(𝑡𝑡)��𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝜸𝜸(𝒕𝒕)�2 ± 2𝑎𝑎(⋆)�𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝜸𝜸(𝒕𝒕)��𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝒋𝒋� + 𝑎𝑎(⋆)�𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝒋𝒋�2�� � 𝜋𝜋𝑗𝑗1−𝜋𝜋𝑗𝑗�𝛾𝛾𝑗𝑗(⋆)−𝛾𝛾𝑗𝑗(𝑡𝑡) , 1�. 
Values of 𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝒋𝒋 ∀ 𝑗𝑗 can be calculated in advance of the MH step, and 𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝜸𝜸(𝒕𝒕) can be easily updated in the sub-
steps if the proposal is accepted by updating to   𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝜸𝜸
(𝒕𝒕) ± 𝒀𝒀�𝑟𝑟𝑟𝑟𝑟𝑟′ 𝒁𝒁𝒋𝒋. 
 
Case-control Whole-Exome Sequencing Study of Prostate Cancer Risk 
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Pathway-based testing was conducted in R using the package SKAT using pathway definitions from KEGG and 
Reactome.  These analyses were conducted on independent samples by selecting a random individual from each of 
the sequenced pedigrees.  The application of the probit BVS method was applied to the same set of samples. 
For analysis, variant sets were formed by aggregating variants within genes and then genes within 
pathways, resulting in a “super gene” testing approach.  Both SKAT-O and burden-based testing were conducted to 
identify significantly associated pathways exhibiting rare variant burden in case subjects.  Variants were included if 
they corresponded to nonsense, missense, or splice site variation.  Variant weighting was defined by functional 
impact, such that nonsense and splice-site variants received weights of 1.0, and missense variants were weighted 
using random forest classification trees built using 15 features from dbNSFP, including 7 functional prediction 
scores.   
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TABLES 
 
  𝑣𝑣 = 5 𝑣𝑣 = 10 𝑣𝑣 = 15 
Method RR TPR FPR TPR  FPR TPR FPR 
P-BRI 1.5 0.341 
(0.323,0.360) 
0.012 
(0.011,0.014) 
0.331 
(0.317,0.344) 
0.014 
(0.013,0.016) 
0.313 
(0.303,0.324) 
0.015 
(0.013,0016) 
L-BRI  0.314 
(0.295,0.333) 
0.017 
(0.015,0.019) 
0.405 
(0.391,0.417) 
0.030 
(0.028,0.033) 
0.434 
(0.423,0.445) 
0.039 
(0.036,0.042) 
P-BRI 2.5 0.694 
(0.677,0.713) 
0.014 
(0.012,0.015) 
0.643 
(0.630,0.656) 
0.014 
(0.013,0.016) 
0.569 
(0.558,0.581) 
0.014 
(0.012,0016) 
L-BRI  0.761 
(0.746,0.779) 
0.035 
(0.033,0.038) 
0.806 
(0.796,0.817) 
0.058 
(0.055,0.061) 
0.784 
(0.774,0.793) 
0.070 
(0.067,0.074) 
P-BRI 5.0 0.972 
(0.966,0.978) 
0.013 
(0.012,0.015) 
0.929 
(0.923,0,936) 
0.014 
(0.013,0.016) 
0.867 
(0.859,0.875) 
0.014 
(0.013,0016) 
L-BRI  0.986 
(0.981,0.990) 
0.039 
(0.036,0.041) 
0.978 
(0.974,0.982) 
0.061 
(0.058,0.064) 
0.965 
(0.961,0.969) 
0.090 
(0.086,0.095) 
Table I:  Simulation results for empirical TPRs and FPRs and corresponding bootstrapped 95% confidence intervals 
for causal RV detection across simulation replications with fixed marginal BF threshold set to 10 (“strong” 
evidence). 
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  True Positive Rate 
Method RR 𝑣𝑣 = 5 𝑣𝑣 = 10 𝑣𝑣 = 15 
P-BRI 1.5 0.324 0.288 0.265 
L-BRI  0.253 0.262 0.250 
Δ (95% CI)  0.070 (0.056,0.086) 0.026 (0.012,0.038) 0.015 (0.002,0.027) 
P-BRI 2.5 0.660 0.603 0.523 
L-BRI  0.638 0.612 0.560 
Δ (95% CI)  0.022 (0.014,0.034) -0.009 (-0.020,0.001) -0.037 (-0.049,-0.022) 
P-BRI 5.0 0.966 0.919 0.845 
L-BRI  0.968 0.929 0.877 
Δ (95% CI)  -0.002 (-0.006,0.001) -0.010 (-0.015,-0.007) -0.032 (-0.039,-0.024) 
Table II:  Simulation results for empirical TPRs for causal RV detection across simulation replications at a fixed 
FPR of 0.01.  For comparisons across methods, the difference in TPR (Δ) and corresponding bootstrap 95% 
confidence interval are reported. 
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 Marginal (BF>10) Marginal (BF>31.6) 
RR TPR  FPR TPR  FPR 
 𝑝𝑝 = 500 
2.5 0.379 
(0.368,0.385) 
0.014 
(0.014,0.015) 
0.235 
(0.228,0.241) 
0.004 
(0.004,0.004) 
5.0 0.605 
(0.596,0.613) 
0.014 
(0.013,0.014) 
0.477 
(0.468,0.486) 
0.004 
(0.004,0.004) 
10.0 0.833 
(0.826,0.840) 
0.012 
(0.012,0.013) 
0.762 
(0.754,0.770) 
0.004 
(0.004,0.004) 
 𝑝𝑝 = 1000 
2.5 0.378 
(0.369,0.386) 
0.013 
(0.013,0.014) 
0.238 
(0.231,0.245) 
0.004 
(0.003,0.004) 
5.0 0.586 
(0.577,0.594) 
0.014 
(0.014,0.014) 
0.454 
(0.445,0.461) 
0.004 
(0.004,0.004) 
10.0 0.801 
(0.794,0.808) 
0.013 
(0.012,0.013) 
0.717 
(0.709,0.725) 
0.004 
(0.004,0.004) 
Table III:  Simulation results for P-BRI in high RV dimensionality (𝑝𝑝 = 500, 1000) for marginal TPR and FPRs at 
traditional BF thresholds (10 and 31.6), along with bootstrap 95% confidence intervals. 
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Chr Position Gene Ref Alt Effect BF 
15 42,364,046 PLA2G4D T C Missense 22.5 
15 42,439,921 PLA2G4F G C Nonsense 82.9 
15 42,448,635 PLA2G4F A C Splice-site 2787.7 
22 38,559,586 PLA2G6 G C Intronic 11.6 
Table IV:  Annotation and marginal BFs for RVs with BF>10 in the post-hoc analysis of 438 RVs implicated in 
pathway RV analysis in prostate cancer risk. 
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FIGURE DESCRIPTIONS 
Figure 1:  Depiction of BFs (y-axis on log10 scale) for all 438 RVs within 26 genes related to pathways previously 
identified to have significant associations with PC risk in the data set.  Colors of the points alternate by gene 
membership from dark gray to light gray, and the y-axis is annotated in the original scale.  Horizontal lines depict 
BF thresholds of 10 and 31.6. 
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